Some of the new drugs such as everolimus (mTOR inhibitor) [122], BYL719, GDC-0941, GDC-0980, and BKM120 (PI3k inhibitors) are being evaluated in combination with fulvestrant for the treatment of breast cancer metastasis [79]. Here, MTOR is linked to breast carcinoma.